Immunoassay for Neurological Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Application, Product, Disease), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Immunoassay for Neurological Biomarkers Market size was over USD 1.17 billion in 2026 and is likely to grow at a 8.46% CAGR between 2027 and 2036, reaching USD 2.64 billion by 2036. The industry revenue for 2027 is calculated at USD 1.25 billion.
Get more details on this report
Request Free Sample ReportImmunoassay for Neurological Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 51.73% of the market in 2026, supported by advanced diagnostic infrastructure, established testing pathways, and widespread use of biomarker-based neurological assessments.
- Asia Pacific is projected to grow at a 19.71% CAGR as healthcare systems expand diagnostic services, research activity increases, and more laboratories adopt biomarker-focused immunoassay platforms.
Segment Momentum
- Research Applications held a 66.12% market share in 2026 because immunoassays are widely used for biomarker discovery, assay validation, and studying disease mechanisms before broader clinical adoption.
- Instruments are the fastest-growing segment as laboratories expand biomarker testing capacity and invest in analytical platforms that improve throughput, workflow efficiency, and standardized testing capabilities.
Market Expansion Drivers
- Rising prevalence of neurodegenerative diseases increasing demand for early diagnostic biomarker testing.
- Expanding pharmaceutical R&D and clinical pipeline accelerating biomarker assay development.
- Growth of precision medicine enabling early disease detection through advanced immunoassay platforms.
Leading Market Participants
- Major companies in the immunoassay for neurological biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (United States), Sysmex Corporation (Japan), Merck KGaA (Germany), Siemens Healthineers AG (Germany), Quanterix Corporation (United States), Fujirebio Holdings, Inc. (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.17 billion
- 2027 Estimated Market Size: USD 1.25 billion.
- Projected Market Size: USD 2.64 billion by 2036
- Growth Forecast: 8.46% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Research Application (Application) | Reagents (Product) | Alzheimer’s Disease (Disease)
- Emerging Opportunity Segment: In Vitro Diagnostics Application (Application) | Instruments (Product) | Alzheimer’s Disease (Disease)
Market Growth Drivers and Industry Trends
Rising prevalence of neurodegenerative diseases increasing demand for early diagnostic biomarker testing
The rising burden of neurodegenerative diseases will drive the immunoassay for neurological biomarkers market by increasing the need for earlier and more reliable identification of disease-related biomarkers. As clinicians seek to detect neurological conditions before significant progression, immunoassay-based testing can support biomarker analysis and strengthen diagnostic workflows. Greater emphasis on early assessment also encourages healthcare providers to incorporate biomarker testing into neurological evaluation, increasing demand for applicable assay platforms and related testing capabilities.
Expanding pharmaceutical R&D and clinical pipeline accelerating biomarker assay development
Expanding pharmaceutical research and clinical development activity will propel the immunoassay for neurological biomarkers market as drug developers increasingly require biomarker tools to support research and clinical evaluation. A broader development pipeline creates demand for assays capable of analyzing neurological biomarkers across research and trial settings, encouraging continued assay development and refinement. This activity also strengthens the role of biomarker testing in pharmaceutical R&D workflows where reliable analytical methods are needed to evaluate disease-related biological changes.
Growth of precision medicine enabling early disease detection through advanced immunoassay platforms
The immunoassay for neurological biomarkers market growth is supported by the expansion of precision medicine, which places greater emphasis on identifying disease characteristics at an earlier stage and tailoring clinical assessment accordingly. Advanced immunoassay platforms can facilitate biomarker-based analysis that complements more individualized approaches to neurological care. As healthcare practices increasingly focus on earlier detection and patient-specific biological information, demand for sophisticated biomarker testing capabilities becomes more closely integrated with precision-oriented diagnostic strategies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising demand for early neurological disease diagnosis | 6.50% | Short term (≤ 2 yrs) | North America, Europe (spillover: Asia Pacific) | High | Fast |
| Expansion of precision medicine & biomarker-based research | 5.80% | Medium term (2–5 yrs) | Asia Pacific, North America (spillover: Europe) | High | Moderate |
| Technological advances in multiplex & digital immunoassays | 4.30% | Long term (5+ yrs) | Europe, North America (spillover: Asia Pacific) | High | Slow |
| Rising prevalence of neurodegenerative diseases increasing demand for early diagnostic biomarker testing | 2.00% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expanding pharmaceutical R&D and clinical pipeline accelerating biomarker assay development | 1.50% | High | North America, Europe | Medium | Mid Term |
| Growth of precision medicine enabling early disease detection through advanced immunoassay platforms | 1.00% | High | North America, Europe, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the immunoassay for neurological biomarkers market, accounting for a 51.73% share in 2026. The region's leading position is supported by its well-established neurological research ecosystem, advanced clinical laboratory infrastructure, and strong adoption of biomarker-based diagnostic approaches. Growing attention to early detection and disease monitoring for neurological disorders is encouraging healthcare providers and research institutions to integrate immunoassay technologies into clinical and investigative workflows. In addition, substantial investment in neuroscience research, increasing availability of specialized diagnostic capabilities, and continued development of sensitive analytical platforms are strengthening regional demand. The presence of sophisticated healthcare systems and favorable conditions for translational research further supports the use of immunoassays for identifying and monitoring neurological biomarkers.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market, driven by expanding healthcare infrastructure, increasing awareness of neurological diseases, and rising demand for advanced diagnostic technologies. Improvements in laboratory capabilities across developing healthcare systems are creating greater opportunities for biomarker testing, while growing investment in medical research is supporting the adoption of more sophisticated analytical methods. The region's large patient population and increasing focus on early diagnosis are also encouraging healthcare institutions to strengthen neurological testing capabilities. Furthermore, expanding access to specialized healthcare services and greater emphasis on precision medicine are expected to support the broader integration of immunoassay-based neurological biomarker testing.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation PriorityGermany emphasizes clinically validated immunoassays for neurological biomarkers that support reliable diagnostic decision-making. Healthcare organizations continue evaluating assays with strong analytical performance for integration into laboratory medicine.
France 🇫🇷
Research-to-Clinical TransitionFrance is reinforcing collaboration between neuroscience research and clinical laboratories to expand the application of immunoassays for neurological biomarkers. Adoption priorities include standardized assays capable of supporting consistent diagnostic interpretation.
Italy 🇮🇹
Laboratory Integration StrategyItaly is strengthening laboratory capabilities for immunoassays targeting neurological biomarkers as demand grows for improved neurological testing. Clinical facilities are focusing on assay platforms that enhance workflow efficiency and diagnostic reliability.
Japan 🇯🇵
Neurodegenerative Testing AdoptionJapan is advancing immunoassay adoption for neurological biomarkers to strengthen assessment of age-related neurological disorders. Laboratories are prioritizing highly sensitive testing platforms that integrate efficiently into established diagnostic workflows.
South Korea 🇰🇷
Innovation-Driven AssaysSouth Korea is encouraging adoption of innovative immunoassays for neurological biomarkers across hospital laboratories and research centers. The focus is on technologies that improve testing efficiency and support precision-focused neurological diagnostics.
United States 🇺🇸
Translational Diagnostics FocusThe U.S. is expanding the use of immunoassays for neurological biomarkers through collaboration between clinical laboratories, hospitals, and research institutions. Demand centers on assays supporting earlier neurological disease assessment and standardized laboratory workflows.
Segment Leadership and Growth Trends
Immunoassay for Neurological Biomarkers Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Research Application (Largest Segment) vs In Vitro Diagnostics Application (Fastest-Growing Segment)
Research application represented the largest segment of the immunoassay for neurological biomarkers market, holding a 66.12% share in 2026. The strong position of research applications is supported by growing scientific interest in identifying and characterizing biomarkers associated with neurological diseases and brain function. Immunoassays provide researchers with practical tools for detecting and quantifying relevant biomolecules, supporting disease research, biomarker validation, and investigation of underlying neurological mechanisms. Increasing emphasis on precision medicine and improved understanding of neurological disorders is further sustaining demand for research-focused immunoassay solutions.
In vitro diagnostics application is the fastest-growing application as healthcare systems increasingly emphasize earlier and more accurate detection of neurological conditions. Neurological biomarkers can support diagnostic assessment and disease monitoring, creating opportunities for immunoassay-based testing to move closer to routine clinical use. Growing demand for minimally invasive diagnostic approaches, advances in biomarker discovery, and increasing attention to personalized disease management are supporting the expansion of in vitro diagnostic applications.
Product Segment Analysis: Reagents (Largest Segment) vs Instruments (Fastest-Growing Segment)
Reagents led the immunoassay for neurological biomarkers market, accounting for a 64.78% share in 2026. Reagents are fundamental to immunoassay workflows because they enable the specific detection and measurement of neurological biomarkers in biological samples. Increasing research activity and the expanding range of biomarkers under investigation are supporting continued consumption of specialized reagents. Demand is also reinforced by the need for reliable, sensitive, and reproducible testing across research and emerging diagnostic applications.
Instruments represent the fastest-growing product segment as laboratories increasingly adopt automated and technologically advanced systems to improve immunoassay workflow efficiency. Modern instruments can support consistent sample processing, analysis, and data generation while reducing manual intervention. Growing laboratory automation, increasing testing complexity, and demand for improved throughput and reproducibility are creating stronger opportunities for advanced immunoassay instrumentation.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | In Vitro Diagnostics Application, Research Application | Research Application | In Vitro Diagnostics Application |
| Product | Instruments, Reagents, Services | Reagents | Instruments |
| Disease | Alzheimer’s Disease, Parkinson's Disease, Multiple Sclerosis, Others | Alzheimer’s Disease | Alzheimer’s Disease |
Competitive Landscape and Market Positioning
Top players in the immunoassay for neurological biomarkers market:
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. Abbott Laboratories (United States)
3. Thermo Fisher Scientific Inc. (United States)
4. QIAGEN N.V. (Netherlands)
5. Bio-Rad Laboratories Inc. (United States)
6. Sysmex Corporation (Japan)
7. Merck KGaA (Germany)
8. Siemens Healthineers AG (Germany)
9. Quanterix Corporation (United States)
10. Fujirebio Holdings Inc. (Japan)
The immunoassay for neurological biomarkers market is expanding with growing emphasis on early and precise neurological disorder detection. Advanced diagnostic methodologies are improving sensitivity and clinical reliability. Increasing innovation in the immunoassay for neurological biomarkers market is supporting broader adoption in complex diagnostic workflows.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Abbott Laboratories (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Sysmex Corporation (Japan) | |||||||
| Merck KGaA (Germany) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Quanterix Corporation (United States) | |||||||
| Fujirebio Holdings Inc. (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Labcorp | Feb-26 | Labcorp launched the FDA-cleared Elecsys pTau-181 blood test nationwide across primary care settings in the U.S., expanding access to Alzheimer’s-related neurological biomarker testing beyond specialty care. The immunoassay-based blood test enables earlier, minimally invasive assessment of amyloid pathology and supports broader clinical integration of neurodegenerative disease diagnostics within routine healthcare workflows. |
| F. Hoffmann-La Roche Ltd. | Oct-25 | Roche received U.S. FDA clearance for its Elecsys pTau181 plasma immunoassay, developed with Eli Lilly, enabling its use in primary care settings to rule out Alzheimer’s-related amyloid pathology. The approval strengthens adoption of blood-based neurological biomarker diagnostics and supports expansion of minimally invasive testing into earlier-stage clinical decision-making pathways. |
| Thermo Fisher | Oct-25 | Thermo Fisher launched the Olink Target 48 Neurodegeneration panel, a proteomics-based immunoassay designed for plasma and CSF biomarker detection in Alzheimer’s, Parkinson’s, and MS research. The solution streamlines neurological biomarker profiling on benchtop instrumentation, strengthening research workflow efficiency and expanding multiplex immunoassay adoption in neurodegeneration studies. |
| Quanterix Corporation | Jul-25 | Quanterix completed the acquisition of Akoya Biosciences to create an integrated blood-and-tissue biomarker platform, strengthening its ultra-sensitive digital immunoassay capabilities. The transaction enhances multiplex biomarker analysis for neurology applications and supports expansion of advanced neurological diagnostic commercialization across research and clinical translational workflows. |
| Quanterix Corporation | Mar-24 | Quanterix received FDA Breakthrough Device Designation for its Simoa p-Tau 217 blood-based immunoassay, intended for assessment of Alzheimer’s-related cognitive impairment risk. The designation accelerates regulatory pathway support for high-sensitivity neurological biomarker diagnostics and reinforces development momentum in digital immunoassay technologies for early neurodegenerative disease detection. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Immunoassay for Neurological Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Biomarker Type | Amyloid Biomarkers, Tau Biomarkers, Neurodegeneration Biomarkers, Neuroinflammation Biomarkers |
| Sample Type | Blood-Based Samples, Cerebrospinal Fluid, Other Biological Samples |
| Testing Setting | Hospital Laboratories, Diagnostic Laboratories, Academic & Research Laboratories |
Immunoassay for Neurological Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathway Assessment |
|
| Biomarker Commercialization Landscape |
|
| Reimbursement Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of immunoassay for neurological biomarkers?
How is the immunoassay for neurological biomarkers industry size expected to evolve during the forecast period?
How is the rise of neurodegenerative disease prevalence shaping demand for immunoassay-based diagnostics?
Why is precision medicine accelerating adoption of neurological biomarker immunoassay platforms?
Why do Research Applications dominate the immunoassay for neurological biomarkers market?
Why are Instruments the fastest-growing product segment in the immunoassay for neurological biomarkers market?
Why does North America lead the immunoassay for neurological biomarkers market?
What is supporting the rapid growth of the immunoassay for neurological biomarkers market in Asia Pacific?
Which companies dominate the immunoassay for neurological biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization